<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958993</url>
  </required_header>
  <id_info>
    <org_study_id>SDZLEC2019-069-03</org_study_id>
    <nct_id>NCT04958993</nct_id>
  </id_info>
  <brief_title>A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Clinical Study of Anlotinib Hydrochloride Capsule Combined With Concurrent Chemoradiotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib&#xD;
      combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage&#xD;
      III non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>up to 30 months</time_frame>
    <description>PFS defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 30 months)</time_frame>
    <description>OS is defined as the time until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to30 months)</time_frame>
    <description>ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment related toxicities</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse events data according to CTCAE version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib combined with concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy: 1.8-2.0Gy, qd, 54-66Gy, 5 days a week Chemotherapy: squamous cell cancer: paclitaxel + platinum;Adenocarcinoma: pemetrexed + platinum;A cycle of 3W was used, and the appropriate chemotherapy dose was selected by the researcher according to the patient's situation without any restriction on the chemotherapy dose.Pre-induction chemotherapy is allowed.&#xD;
Anlotinib: QD, take 2 weeks and stop for 1 week (radiotherapy 1, 2, 4, 5 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy</intervention_name>
    <description>radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)</description>
    <arm_group_label>Anlotinib combined with concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. The patients volunteered to participate in this study and signed the informed&#xD;
             consent;&#xD;
&#xD;
          -  2. Pathologically confirmed as a newly diagnosed and unresectable locally advanced&#xD;
             non-small cell lung cancer (STAGE IIIA/ IIIB) with measurable lesions;IIIa3:&#xD;
             Multistation lymph node metastases detected by mediastinoscopy, other lymph node&#xD;
             biopsy, or PET/CT;IIIa4: Massive or fixed multistation N2 lymph node metastasis&#xD;
             (massive lymph nodes, defined as lymph nodes with a short diameter of more than 2 cm&#xD;
             on a helical CT scan, especially those with extranode invasion).;Patients with IIIb.In&#xD;
             addition, T3/4 with multiple satellite nodules in the ipsilateral or contralateral&#xD;
             lung was not included in this study.&#xD;
&#xD;
          -  3. Patients with negative EGFR, ALK and ROS1 gene test results;&#xD;
&#xD;
          -  4. Ages 18-75, regardless of gender;&#xD;
&#xD;
          -  5. ECOG score: 0-1;&#xD;
&#xD;
          -  6. Expected survival over 3 months;&#xD;
&#xD;
          -  7. Function of major organs within 7 days prior to treatment meets the following&#xD;
             criteria:&#xD;
&#xD;
        A. Standard of blood routine examination (without blood transfusion within 14 days) :&#xD;
&#xD;
        I. Hemoglobin (HB) ≥100 g/L; II. WBC ≥3.0×109/L; Iii. Platelet (PLT) ≥100×109/L.&#xD;
&#xD;
        B. Biochemical examination shall meet the following standards:&#xD;
&#xD;
        I. Total bilirubin (TBIL) ≤1.5 times the upper limit of normal value (ULN); II. AST≤2.5×ULN&#xD;
        of alanine aminotransferase (ALT) and aspartate aminotransferase (ASpartate), if&#xD;
        accompanied by liver metastasis, ALT and AST≤5×ULN; III. Serum creatinine (Cr) ≤1.5×ULN or&#xD;
        creatinine clearance rate (CCr)≥60ml/min; C. Doppler ultrasound evaluation: left&#xD;
        ventricular ejection fraction (LVEF) ≥ lower normal limit (50%); D. Pulmonary function&#xD;
        assessment: FEV1≥1.45 l/s.&#xD;
&#xD;
          -  8. Patients of childbearing age (including female and female partners of male&#xD;
             patients) must take effective birth control measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients who have previously used anlotinib hydrochloride capsules;&#xD;
&#xD;
          -  2. Small cell lung cancer (including mixed small cell and non-small cell cancers);&#xD;
&#xD;
          -  3. Lung squamous cell carcinoma with empty cavity, or non-small cell lung cancer with&#xD;
             hemoptysis (&gt; 20ml/day);&#xD;
&#xD;
          -  4. Patients with other malignant tumors other than NSCLC within 5 years before the&#xD;
             start of treatment in this study (except those with simple surgical resection and&#xD;
             disease-free survival for at least 5 consecutive years, cured cervical carcinoma in&#xD;
             situ, cured basal cell carcinoma and bladder epithelial tumor);&#xD;
&#xD;
          -  5. Systemic antitumor therapy, including cytotoxic therapy, signal transduction&#xD;
             inhibitors and immunotherapy, is planned within 4 weeks before enrollment or during&#xD;
             the medication period of this study.In addition to thymosin, lentinan and other&#xD;
             immunomodulator treatment.&#xD;
&#xD;
          -  6. Unmitigated toxicity due to any previous treatment above CTC AE level 1, excluding&#xD;
             hair loss;&#xD;
&#xD;
          -  7. Patients with multiple factors affecting oral medication (such as inability to&#xD;
             swallow, chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          -  8. Accompanied by pleural effusion or ascites, causing respiratory syndrome (≥CTC AE&#xD;
             level 2 dyspnea);&#xD;
&#xD;
          -  9. Patients with any severe and/or uncontrolled disease, including: A) Patients with&#xD;
             unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg, diastolic&#xD;
             blood pressure ≥100 mmHg); B) Having grade I or above myocardial ischemia or&#xD;
             infarction, arrhythmia (including QTc ≥480ms), and grade 2 or above congestive heart&#xD;
             failure (New York Heart Association (NYHA) classification); C) Active or uncontrolled&#xD;
             severe infection (≥CTC AE level 2 infection); D) Antiviral treatment for cirrhosis,&#xD;
             decompensated liver disease, active hepatitis or chronic hepatitis; E) Renal failure&#xD;
             requires hemodialysis or peritoneal dialysis; F) A history of immunodeficiency,&#xD;
             including HIV positive or other acquired or congenital immunodeficiency diseases, or a&#xD;
             history of organ transplantation; G) poor control of diabetes mellitus (FBG) &gt;&#xD;
             10mmol/L; H) urine routine indicated urinary protein ≥++, and confirmed 24-hour&#xD;
             quantitative urinary protein &gt; 1.0g; I) patients with epileptic seizures requiring&#xD;
             treatment; J) Patients with gastric ulcer&#xD;
&#xD;
          -  10. Receive major surgical treatment, open biopsy or significant traumatic injury&#xD;
             within 28 days before grouping;&#xD;
&#xD;
          -  11. Patients whose tumors have invaded important blood vessels according to imaging&#xD;
             findings or whose tumors are likely to invade important blood vessels during the&#xD;
             follow-up study according to the judgment of the researchers, resulting in fatal&#xD;
             massive hemorrhage;&#xD;
&#xD;
          -  12. Patients with any physical signs or history of bleeding, regardless of&#xD;
             severity;Patients with any bleeding or bleeding event ≥CTCAE level 3 within 4 weeks&#xD;
             prior to enrollment have unhealed wounds, ulcers or fractures;&#xD;
&#xD;
          -  13. Occurrence of ARTERIAL/venous thrombotic events, such as cerebrovascular accidents&#xD;
             (including temporary ischemic attacks), deep venous thrombosis and pulmonary embolism&#xD;
             within 6 months;&#xD;
&#xD;
          -  14. Persons with a history of abuse of psychotropic substances and who cannot be cured&#xD;
             or have mental disorders;&#xD;
&#xD;
          -  15. Pregnant and lactating women;&#xD;
&#xD;
          -  16. Participated in other clinical trials of anti-tumor drugs within 4 weeks;&#xD;
&#xD;
          -  17. The researcher considered that there were other conditions that were not suitable&#xD;
             for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JINGMIN YU, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JINGMIN YU, PhD</last_name>
    <phone>8613806406293</phone>
    <email>jn7984729@public.jn.sd.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HUI ZHU, PhD</last_name>
    <phone>8615805310022</phone>
    <email>drzhuhui@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JINMING YU, PhD</last_name>
      <phone>8613806406293</phone>
      <email>jn7984729@public.jn.sd.cn</email>
    </contact>
    <contact_backup>
      <last_name>HUI ZHU, PhD</last_name>
      <phone>15805310022</phone>
      <email>drzhuhui@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>Director of the hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

